GlaxoSmithKline : Q2 2022 US dollar translation ( - 0b)

Income statement

			Q2 2022			Q2 2022			H1 2022			H1 2022
			£m			$m			£m			$m
TURNOVER	6,929	8,700	14,119	18,288
Cost of sales		(2,176)		(2,732)		(4,893)		(6,338)
Gross profit	4,753	5,968	9,226	11,950
Selling, general and administration	(2,066)	(2,594)	(3,878)	(5,023)
Research and development	(1,242)	(1,559)	(2,345)	(3,037)
Royalty income	159	200	297	385
Other operating income/(expenses)		(523)		(658)		74		95
OPERATING PROFIT	1,081	1,357	3,374	4,370
Finance income	21	26	28	36
Finance expense	(204)	(255)	(409)	(529)
Share of after tax losses of associates and	joint		(3)		(3)
ventures		(2)		(4)
PROFIT BEFORE TAXATION	896	1,125	2,990	3,873
Taxation		(150)		(188)		(473)		(613)
PROFIT AFTER TAXATION FROM CONTINUING
OPERATIONS	746	937	2,517	3,260
PROFIT AFTER TAXATION FROM
DISCONTINUED OPERATIONS	229	288	625	810
PROFIT AFTER TAXATION FROM THE
PERIOD		975		1,225		3,142		4,070
Profit attributable to non-controlling interests from
continuing operations	40	50	315	408
Profit attributable to shareholders from continuing
operations	706	887	2,202	2,852
Profit attributable to non-controlling interests
from discontinued operations	97	122	187	242
Profit attributable to shareholders from
discontinued operations		132		166		438		568
		975		1,225		3,142		4,070
Profit attributable to non-controlling interests	137	172	502	650
Profit attributable to shareholders	838	1,053	2,640	3,420
			975			1,225			3,142			4,070
EARNINGS PER SHARE FROM CONTINUING
OPERATIONS			17.5p			22.0p			54.8p			71.0p
EARNINGS PER SHARE FROM
DISCONTINUED OPERATIONS			3.3p			4.1p			10.9p			14.1p
TOTAL EARNINGS PER SHARE
		20.8p			26.1p			65.7p			85.1p
Diluted earnings per share from continuing
operations			17.4p			21.9p	54.3¢	70.3¢
Diluted earnings per share from discontinued
operations			3.2p			4.0p		10.7¢			13.9p¢
Total diluted earnings per share			20.6p			25.9p	65.0¢	84.2¢

US dollar amounts shown in the income statement above are a convenience translation of the sterling amounts. US dollar results for the three and six months periods ended 30 June 2022 are calculated using average rates for the periods.

US dollar amounts for the detailed sales tables below are a convenience translation of the sterling amounts. US dollar results for the six months ended 30 June 2022 are calculated using average rates for the period. US dollar results for the three months ended 30 June 2022 are calculated as the difference between these six months results translated into US dollars and US dollar results previously published for the three months ended 31 March 2022.

Specialty Medicines turnover - three months ended 30 June 2022

											Inter-												Inter-
		Total			US			Europe			national			Total			US			Europe			national
		£m			£m			£m			£m			$m			$m			$m			$m
HIV
1,404	894	336	174	1,770	1,131	423	216
Dolutegravir products	1,279	796	320	163	1,613	1,006	403	204
Tivicay	346	201	72	73	436	255	90	91
Triumeq	461	307	97	57	582	388	122	72
Juluca	152	116	33	3	191	146	42	3
Dovato	320	172	118	30	404	217	149	38
Rukobia	19	18	-	1	24	23	-	1
Cabenuva	72	63	8	1	91	80	10	1
Apretude	8	8	-	-	10	10	-	-
Other	26	9	8	9	32	12	10	10
Oncology	154	83	62	9	194	105	77	12
Zejula
120	63	48	9	151	80	60	11
Blenrep	30	19	11	-	38	24	14	-
Jemperli	4	1	3	-	5	1	3	1
Immuno-inflammation,
respiratory and other	680	487	92	101	860	617	116	127
Benlysta
297	251	20	26	376	318	26	32
Nucala	367	236	74	57	463	299	93	71
Specialty Medicines
excluding pandemic	2,238	1,464	490	284	2,826	1,852	617	357
Pandemic	466	23	123	320	552	(1)	147	406
Xevudy
466	23	123	320	552	(1)	147	406
Specialty Medicines
2,704	1,487	613	604	3,378	1,852	765	761

Specialty Medicines turnover - six months ended 30 June 2022

											Inter-												Inter-
		Total			US			Europe			national			Total			US			Europe			national
		£m			£m			£m			£m			$m			$m			$m			$m
HIV
2,585	1,591	635	359	3,347	2,061	822	464
Dolutegravir products	2,381	1,437	607	337	3,084	1,861	786	437
Tivicay	666	361	137	168	863	468	177	218
Triumeq	853	552	191	110	1,105	715	247	143
Juluca	285	215	63	7	369	278	82	9
Dovato	577	309	216	52	747	400	280	67
Rukobia	35	33	1	1	45	43	1	1
Cabenuva	110	95	14	1	142	123	18	1
Apretude	10	10	-	-	13	13	-	-
Other	49	16	13	20	63	21	17	25
Oncology	281	152	116	13	363	197	149	17
Zejula
218	114	91	13	282	148	117	17
Blenrep	55	35	20	-	71	45	26	-
Jemperli	8	3	5	-	10	4	6	-
Immuno-inflammation,
respiratory and other	1,200	834	176	190	1,554	1,080	228	246
Benlysta
512	421	39	52	663	545	51	67
Nucala	662	413	139	110	857	535	180	142
Specialty Medicines
excluding pandemic	4,066	2,577	927	562	5,267	3,338	1,201	728
Pandemic	1,773	793	434	546	2,297	1,027	562	708
Xevudy
1,773	793	434	546	2,297	1,027	562	708
Specialty Medicines
5,839	3,370	1,361	1,108	7,563	4,365	1,763	1,435

Vaccines turnover - three months ended 30 June 2022

											Inter-												Inter-
		Total			US			Europe			national			Total			US			Europe			national
		£m			£m			£m			£m			$m			$m			$m			$m
Meningitis
235	120	87	28	296	152	109	35
Bexsero
165	65	81	19	207	82	101	24
Menveo	69	55	5	9	88	70	6	12
Other	1	-	1	-	1	-	2	(1)
Influenza	32	1	-	31	41	2	-	39
Fluarix, FluLaval
32	1	-	31	41	2	-	39
Shingles	731	519	151	61	919	653	189	77
Shingrix
731	519	151	61	919	653	189	77
Established Vaccines	717	257	176	284	900	321	221	358
Infanrix, Pediarix
120	51	31	38	148	61	39	48
Boostrix	158	95	38	25	200	121	48	31
Hepatitis	159	98	39	22	201	124	49	28
Rotarix	120	14	29	77	152	16	36	100
Synflorix	84	-	10	74	106	-	13	93
Priorix, Priorix Tetra,	40	-	23	17	50	-	29	21
Cervarix	22	-	4	18	27	-	5	22
Other	14	(1)	2	13	16	(1)	2	15
Vaccines excluding
pandemic	1,715	897	414	404	2,156	1,128	520	509
Pandemic vaccines	-	-	-	-	-	-	-	-
Pandemic adjuvant	-	-	-	-	-	-	-	-
Vaccines
1,715	897	414	404	2,156	1,128	520	509

Vaccines turnover - six months ended 30 June 2022

											Inter-												Inter-
		Total			US			Europe			national			Total			US			Europe			national
		£m			£m			£m			£m			$m			$m			$m			$m
Meningitis
447	219	170	58	579	284	220	75
Bexsero
328	131	160	37	425	170	207	48
Menveo	111	88	8	15	144	114	10	20
Other	8	-	2	6	10	-	3	7
Influenza	50	2	-	48	65	3	-	62
Fluarix, FluLaval
50	2	-	48	65	3	-	62
Shingles	1,429	1,009	311	109	1,851	1,307	403	141
Shingrix
1,429	1,009	311	109	1,851	1,307	403	141
Established Vaccines	1,458	559	342	557	1,889	724	443	722
Infanrix, Pediarix
295	163	60	72	382	211	78	93
Boostrix	284	165	71	48	368	214	92	62
Hepatitis	281	176	68	37	364	228	88	48
Rotarix	237	49	61	127	307	63	79	165
Synflorix	165	-	16	149	214	-	21	193
Priorix, Priorix Tetra,	87	-	51	36	113	-	66	47
Cervarix	51	-	8	43	66	-	10	56
Other	58	6	7	45	75	-	9	58
Vaccines excluding
pandemic	3,384	1,789	823	772	4,384	2,318	1,066	1,000
Pandemic vaccines	-	-	-	-	-	-	-	-
Pandemic adjuvant	-	-	-	-	-	-	-	-
Vaccines
3,384	1,789	823	772	4,384	2,318	1,066	1,000